JP2020506962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506962A5 JP2020506962A5 JP2019560066A JP2019560066A JP2020506962A5 JP 2020506962 A5 JP2020506962 A5 JP 2020506962A5 JP 2019560066 A JP2019560066 A JP 2019560066A JP 2019560066 A JP2019560066 A JP 2019560066A JP 2020506962 A5 JP2020506962 A5 JP 2020506962A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hla
- antibody
- neoantigen
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 74
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 74
- 210000004027 cell Anatomy 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- ICTPRLMOGAKCOZ-HWVMREAWSA-N NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O)C(C)C)CC1=CC=C(O)C=C1 Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O)C(C)C)CC1=CC=C(O)C=C1 ICTPRLMOGAKCOZ-HWVMREAWSA-N 0.000 claims 4
- 102000028650 human MAGE-A1 protein (278-286) Human genes 0.000 claims 4
- 108091005020 human MAGE-A1 protein (278-286) Proteins 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 claims 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 2
- 108010024164 HLA-G Antigens Proteins 0.000 claims 2
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 claims 2
- 101000993059 Homo sapiens Hereditary hemochromatosis protein Proteins 0.000 claims 2
- 101000866971 Homo sapiens Putative HLA class I histocompatibility antigen, alpha chain H Proteins 0.000 claims 2
- 102100031498 Putative HLA class I histocompatibility antigen, alpha chain H Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000004581 coalescence Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023102868A JP2023134503A (ja) | 2017-01-24 | 2023-06-22 | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449954P | 2017-01-24 | 2017-01-24 | |
| US62/449,954 | 2017-01-24 | ||
| US201762460585P | 2017-02-17 | 2017-02-17 | |
| US62/460,585 | 2017-02-17 | ||
| PCT/US2018/015086 WO2018140525A1 (en) | 2017-01-24 | 2018-01-24 | Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023102868A Division JP2023134503A (ja) | 2017-01-24 | 2023-06-22 | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506962A JP2020506962A (ja) | 2020-03-05 |
| JP2020506962A5 true JP2020506962A5 (enExample) | 2021-03-04 |
| JP7303750B2 JP7303750B2 (ja) | 2023-07-05 |
Family
ID=62979691
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560066A Active JP7303750B2 (ja) | 2017-01-24 | 2018-01-24 | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
| JP2023102868A Pending JP2023134503A (ja) | 2017-01-24 | 2023-06-22 | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023102868A Pending JP2023134503A (ja) | 2017-01-24 | 2023-06-22 | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190071502A1 (enExample) |
| EP (1) | EP3573997A4 (enExample) |
| JP (2) | JP7303750B2 (enExample) |
| CN (1) | CN110809580A (enExample) |
| WO (1) | WO2018140525A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211754T1 (hr) | 2014-12-23 | 2022-03-04 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| EP3539552A1 (en) * | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| EP3827021A4 (en) * | 2018-07-23 | 2022-08-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | ANTIBODIES DIRECTED TO A NON-CLASSIC HLA-I/NEOANTIGEN COMPLEX AND THEIR USE |
| KR20210089193A (ko) * | 2018-11-01 | 2021-07-15 | 버클리 라잇츠, 인크. | 미세유체 디바이스에서 생물학적 세포를 분석하기 위한 방법 |
| CN114341172A (zh) * | 2019-07-05 | 2022-04-12 | 英特莱克森有限责任公司 | 医学和诊断学中的hla-h |
| CN110491450B (zh) * | 2019-08-23 | 2023-05-16 | 深圳市新合生物医疗科技有限公司 | 肿瘤新生抗原预测平台及其应用 |
| CN114846156A (zh) * | 2019-10-25 | 2022-08-02 | 英特莱克森有限责任公司 | Hla-h、hla-j、hla-l、hla-v和hla-y作为治疗和诊断靶 |
| JP2023527293A (ja) * | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | Ｍａｇｅｂ２結合構築物 |
| US10981996B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US10981997B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| JP7620780B2 (ja) * | 2020-06-30 | 2025-01-24 | ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 |
| US20250051454A1 (en) * | 2020-09-15 | 2025-02-13 | Duke University | Antibodies that target hla-e-host peptide complexes and uses thereof |
| CA3229447A1 (en) * | 2021-08-20 | 2023-02-23 | Duke University | Antibodies that target hla-e-host peptide complexes and uses thereof |
| EP4450518A4 (en) * | 2021-12-15 | 2025-11-26 | Teikyo Heisei Univ | VHH ANTIBODIES |
| CA3268204A1 (en) * | 2022-10-05 | 2024-04-11 | Tscan Therapeutics Inc | MAGEA1 IMMUNOGENEOUS PEPTIDES, MAGEA1 IMMUNOGENEOUS PEPTIDE-BINDING PROTEINS, AND THEIR USES |
| WO2024084091A1 (en) * | 2022-10-21 | 2024-04-25 | Medizinische Universität Wien | Materials and methods to treat epstein-barr virus (ebv) and ebv-induced diseases |
| TW202513802A (zh) * | 2023-09-22 | 2025-04-01 | 美商再生元醫藥公司 | 獲得與多肽－ｍｈｃ界面結合的抗體分子之方法 |
| GB202316281D0 (en) * | 2023-10-24 | 2023-12-06 | Replay Holdings Inc | Methods and compositions for modulating immune cell activity in cellular therapy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI9809391B8 (pt) * | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| ATE533784T1 (de) * | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
| GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| DE60142615D1 (de) * | 2000-04-28 | 2010-09-02 | Mannkind Corp | Epitop-synchronisierung in antigen präsentierenden zellen |
| CN101663047B (zh) | 2007-02-23 | 2014-07-09 | 纽约哥伦比亚大学理事会 | 通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法 |
| US20100158927A1 (en) * | 2007-03-29 | 2010-06-24 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| GB201003198D0 (en) * | 2010-02-25 | 2010-04-14 | Arab Biotechnology Company | Compositions and methods for the treatment of cancer |
| KR20130049196A (ko) * | 2010-08-05 | 2013-05-13 | 에프. 호프만-라 로슈 아게 | 항-mhc 항체 항-바이러스성 사이토카인 융합 단백질 |
| WO2013075105A2 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Tcl1 peptides for immunotherapy |
| US10656156B2 (en) * | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| TW202446953A (zh) * | 2013-12-04 | 2024-12-01 | 日商中外製藥股份有限公司 | 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫 |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| WO2016210365A2 (en) * | 2015-06-24 | 2016-12-29 | Eureka Therapeutics, Inc. | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
-
2018
- 2018-01-24 JP JP2019560066A patent/JP7303750B2/ja active Active
- 2018-01-24 WO PCT/US2018/015086 patent/WO2018140525A1/en not_active Ceased
- 2018-01-24 CN CN201880020694.1A patent/CN110809580A/zh active Pending
- 2018-01-24 EP EP18745174.5A patent/EP3573997A4/en active Pending
- 2018-08-14 US US16/103,764 patent/US20190071502A1/en not_active Abandoned
-
2023
- 2023-06-22 JP JP2023102868A patent/JP2023134503A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506962A5 (enExample) | ||
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| MY207205A (en) | Cd3 antibody and pharmaceutical use thereof | |
| JP2015535691A5 (enExample) | ||
| PH12016502370A1 (en) | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof | |
| JP2015535689A5 (enExample) | ||
| JP2022048153A5 (enExample) | ||
| CR20200014A (es) | Molécula de polipéptido con especificidad dual mejorada | |
| WO2020052692A3 (en) | Binding molecules against cd3 and uses thereof | |
| MX375379B (es) | Receptores de celulas t anti - papilomavirus 16 e7 humano. | |
| JP2018524987A5 (enExample) | ||
| JP2012197278A5 (enExample) | ||
| JP2020524506A5 (enExample) | ||
| JP2017537972A5 (enExample) | ||
| Monroy-García et al. | Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model | |
| JO3744B1 (ar) | مواد ربط لـpd1 و/ أو lag3 | |
| MX2020010460A (es) | Receptores de células t, y células diseñadas que expresan los mismos. | |
| JP2017513478A5 (enExample) | ||
| JP2020500523A5 (enExample) | ||
| JP2019527041A5 (enExample) | ||
| JP2016500251A5 (enExample) | ||
| MX2020009475A (es) | Inmunoterapia con celulas car de anticuerpos biespecificos. | |
| JP2018504143A5 (enExample) | ||
| JP2015083010A5 (enExample) | ||
| JP2019522054A5 (enExample) |